Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors

Amatuximab is a chimeric monoclonal antibody that targets mesothelin, which is expressed in virtually all mesotheliomas and pancreatic adenocarcinomas. The objective of this study was to determine the dose-limiting toxicity and the maximum tolerated dose. Patients with mesothelioma, pancreatic adeno...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Invest New Drugs
Autors principals: Fujisaka, Yasuhito, Kurata, Takayasu, Tanaka, Kaoru, Kudo, Toshihiro, Okamoto, Kunio, Tsurutani, Junji, Kaneda, Hiroyasu, Okamoto, Isamu, Namiki, Masayuki, Kitamura, Chifumi, Nakagawa, Kazuhiko
Format: Artigo
Idioma:Inglês
Publicat: Springer US 2014
Matèries:
Phase I Studies
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4387254/
https://ncbi.nlm.nih.gov/pubmed/25502863
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-014-0196-0
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars